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Monoamine oxidase (MAO) is a flavinic enzyme, with two isoforms (A and B), located at the outer
mitochondrial membrane that constantly generate hydrogen peroxide (H2O2) as by-product of their catalytic
cycle. We investigated the role of monoamine oxidase (MAO) in development of endothelial dysfunction in
isolated dog carotid arteries after in vitro exposure to angiotensin 2 (Ang II). Canine carotid artery segments
were incubated with Ang II in the presence or absence of moclobemide (a reversible MAO-A inhibitor) or
catalase. Subsequently, the fragments were used for organ bath studies of vascular reactivity and for the
hydrogen peroxide measurements. Pretreatment of vascular rings revealed that incubation with Ang elicited
endothelial dysfunction via H2O2 production whereas co-treatment with moclobemide reduced the H2O2
levels and improved the vascular function in Ang II-treated vessels; in presence of L-NAME the effect of
moclobemide was absent. In conclusion, MAO is an important source of ROS production, activated in response
to Ang II and treatment with MAO inhibitors represents a possibility to reverse this negative effect.
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The endothelium is the main target of cardiovascular
risk factors, being mostly involved in the progression of
vascular inflammation and atherosclerosis. Although low
levels of reactive oxygen species (ROS) play a key role as
signaling molecules, elevated levels of ROS are major
contributors to the pathophysiology of cardiovascular
dysfunction. The enzymatic systems currently considered
responsible for the generation of reactive oxygen species
(ROS) in the development of endothelial dysfunction via
limiting the bioavailability of nitric oxide (NO) are: NADPH
oxidases, xanthine oxidase, mitochondrial respiratory
chain, cyclooxygenase, lipooxygenase and uncoupled
endothelial NO synthase (eNOS) [1-6]. In the past decade
novel mitochondrial enzymes have been characterized as
unequivocal sources of oxidative stress. Monoamine
oxidases (MAOs) are flavoenzymes, with two isoforms,
MAO-A and MAO-B, located at the outer mitochondrial
membrane that constantly generate H2O2 as by-product of
their catalytic cycle [7-9]. The primary physiological role
of MAO is the degradation of endogenous monoamine
neurotransmitters and exogenous amines. In peripheral
tissues, MAO is involved in oxidative catabolism of amines
and prevention of the ingress of dietary amines (such as
tyramine from fermented cheese) in circulation [10].
MAOs have been extensively studied for their
involvement in pathogenesis of neurodegenerative and
psychiatric diseases [7, 11]. In this regard, a wide range of
MAO inhibitors (MAOIs) are available and proven to have
therapeutic value in several pathologies, including affective
disorders, neurodegenerative diseases, stroke and
senescence [7]. MAOIs are classified into 3 categories: i)
non-selective irreversible inhibitors such as phenelzine and
tranylcypromine; ii) irreversible and selective inhibitors
such as selegiline for MAO-B and clorgyline for MAO-A; iii)
reversible and selective inhibitors such as moclobemide
for MAO-A and lazabemide for MAO-B. Despite the fact
that MAO inhibitors are not the most widely prescribed
antidepressants, they still represent an important
therapeutic option in psychiatric and neurological diseases
[10] being also recognized in recent years for their
neuroprotective properties [12]. In this regard,
moclobemide (a reversible inhibitor of MAO-A) was found
to have anti-parkinsonian activity and neuroprotective
effects in a model of cerebral ischemia via MAO-A inhibition
and also independent of this effect [7, 10].
In the past decade, MAO has been reported to contribute
to the ischemia-reperfusion injuries in kidney [13] and heart
[14], and in maladaptive cardiomyocyte hypertrophy and
its evolution to heart failure [15]. However, less information
is available in the literature with regard to the effect of
MAO in vasculature. Accordingly, one study reported a
significant reduction in contractility of the basilar arteries
harvested from the hypertensive by the treatment with
MAO-A inhibitors [16]. In another study the treatment with
angiotensin II converting enzyme inhibitors reduced MAO
activity, suggesting that hyperactivation of renin-
angiotensin-aldosterone system will potentiate the enzyme
activity [17]. We previously reported an increased
expression of both MAO isoforms in two murine models
associated with vascular inflammation and hypertension
responsible for subsequent endothelial dysfunction that
was partially reversed by MAO inhibitors [18].
In the present study we aimed at assessing the effect of
angiotensin II exposure on MAO in canine carotid vascular
segments. We hypothesized that in vitro treatment with
Ang II will impair vascular relaxation in a MAO-dependent
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Canine vascular segments were obtained from adult
mongrel dogs of either sex weighing 8-16 kg from the
Department of Pharmacology and Pharmacotherapy,
University of Szeged, Hungary within the framework of a
collaborative research mobility. All the experimental
procedures were conducted in accordance with the
Directive 2010/63/EU regarding the protection of animals
used for scientific purposes. The protocols were approved
by the review board of the Department of Animal Health
and Food Control of the Ministry of Agriculture and Rural
Development, Hungary (XII./01031/000/2008 and XIII./
1211/2012).
Organ Culture
 Carotid artery segments were dissected under sterile
conditions, cleaned, and incubated for the times indicated
at 37°C in EBM culture medium containing 0.1% BSA, in
the presence or absence of angiotensin II (100 nmol/L)
with or without moclobemide (10 microM, Sigma-Aldrich)
or PEG-Catalase (100 U/mL, Sigma-Aldrich). Subsequently,
the tissue was used for organ bath experiments and for
ROS measurement, respectively.
Studies of Vascular Function
Vascular function of carotid artery rings was studied in
the presence of diclofenac (10 μmol/L). The concentration
of phenylephrine, used for preconstriction, was adjusted
to obtain an identical preconstriction level of 80% of the
contraction elicited by KCl (80 mmol/L). Endothelium-
dependent relaxation to cumulatively increasing
concentrations of acetylcholine was recorded.
Measurements of Reactive Oxygen Species
Hydrogen peroxide production was measured in carotid
segments by the Ferric iron xylenol orange oxidation
method (FOX Assay, Sigma Aldrich) as previously reported
[18]. The principle of the assay is that peroxides oxidize
Fe2+ to Fe3+ ions at acidic pH. The  Fe3+ ion  will  form  a
coloured  adduct  with  xylenol  orange (XO, 3,33’ -carboxy-
methyl)aminomethyl]-o-cresolsulfonephthalein, sodium
salt), which is observed at  (XO, 3,33’ -bis[N,Nbis (carboxy-
methyl)aminomethyl]-o-cresolsulfonephthalein, sodium
salt), which is observed at 560 nm.
Statistics
All values are expressed as mean ± SEM and were
analysed using one-way ANOVA and Tukey’s post hoc
analysis. Relaxations were calculated from individual dose-
response curves. Data analysis of the dose-effect response
curves was performed using the ANOVA F-test
(comparisons of bottom and top values, EC50 and the Hill
slope). Values of p<0.05 were considered statistically
significant.
Results and discussions
In vitro treatment of carotid arteries with Ang II elicited
H2O2 –mediated endothelial dysfunction
Incubation of vascular rings with Ang II is a classical
method to induce in vitro endothelial dysfunction. There is
unanimous consensus in the literature regarding the major
role of superoxide anion (O2
-) in mediating endothelial
dysfunction. In the present study we questioned the
contribution of H2O2 production after Ang II stimulation to
the vascular dysfunction of canine carotid rings. To this
aim we incubated the vascular preparations for 24 h with
Ang II (100 nmol/L) in the presence vs. the absence of the
H2O2 scavenger catalase (100 U/ml). The vascular
contractility in response to phenylephrine after Ang II
stimulation was significantly increased as compared to
the non-treated rings and this effect was reduced by the
presence of catalase (fig. 1A). Also, after Ang II treatment
the endothelium-dependent relaxation was significantly
impaired. This effect was partially attenuated by co-
incubation with catalase (fig. 1B). Finally, we evaluated by
means of the FOX assay, the H2O2 production in vessels
treated with Ang II vs. control in the presence or absence
of catalase. The results showed a significant increase in
H2O2 production, effect that was partially attenuated in the
presence of catalase (fig.1C). Thus we confirmed the
contribution of H2O2 to the Ang II-induced endothelial
dysfunction in isolated carotid rings.




 in functional vascular impairment induced
by in vitro treatment with Ang II. A)  Phenylephrine-induced
contractions, n=6, *p<0.05 with and without Ang II treatment, #
p<0.05 with and without catalase (PEG-Catalase, 100 U/mL). B)
Acetylcholine-induced endothelium-dependent relaxation. n=6,
*p<0.05 with and without Ang II treatment, #p<0.05 with and
without Catalase. C) H2O2 formation by FOX assay in the presence
vs. absence of PEG-catalase (100 U/mL), n=6, *p<0.05 with and
without Ang II treatment, #p<0.05 with and without catalase
Co-treatment with MAO inhibitor reduced the H2O2
production and improved vascular function in Ang II-treated
preparations
MAOs are constant sources of mitochondrial H2O2
production. Whether MAO-derived H2O2 contributes to the
endothelial dysfunction induced by Ang II in canine has
not been previously investigated. We treated carotid
arteries with Ang II in the presence vs. the absence of
moclobemide, the reversible MAO-A inhibitor. Ang II
induced a strong attenuation of the endothelium-
dependent relaxation in response to acetylcholine. Co-
incubation with MAO-A inhibitor restored partially the
relaxation response (fig. 2A) and the level of H2O2 (fig. 2B).
Inhibition of eNOS by L-NAME prevented the beneficial
effects of MAO inhibition
In order to investigate the mechanism underlying the
MAO-induced endothelial dysfunction after Ang II
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stimulation, we assessed the effect of endothelial NO
synthase (eNOS) inhibition with L-NAME in vessels treated
with Ang II with and without  moclobemide. Interestingly,
in Ang II-treated carotid arteries, after eNOS inhibition,
moclobemide had no further beneficial effects on the
endothelial-dependent relaxation (fig. 3). These results
suggest that one of the pathways affected by MAO derived
H2O2 includes eNOS and NO signalling. If eNOS is
suppressed MAOi fail to improve the vascular response.
Results and discussions
In this study we were focused on the role of MAO in
development of endothelial dysfunction in experimental
setting using Ang II as promotor of the vascular impairment.
We have previously demonstrated in the murine model
that Ang II elicited a significant increase in the amount of
H2O2 generated in isolated vascular preparations [19]. We
confirm that this is also the case in the canine model of in
vitro induced endothelial dysfunction as determined by the
FOX assay. We also report that at least partially H2O2 is
generated via the MAO-A isoform. In fact, Ang II elicited a
2 times-increase in the H2O2 production in aortic rings
whereas incubation (30 min) with moclobemide, the MAO-
A inhibitor, reduced by 50% the amount of this ROS.
 The level of H2O2 generated via this mitochondrial
enzyme induced a serious alteration of the vascular
relaxation in Ang II-treated vascular segments. This effect
was partial, but significantly improved in the presence of
moclobemide.
Another important finding of this study is that, in control
vessels, MAO inhibition did not interfere with H2O2
production and vascular reactivity, suggesting that in basal
conditions MAO activity is reduced and the amount of ROS
produced is low and thus unable to induce endothelial
dysfunction.
Increased production of reactive oxygen species is
associated to different type of pathologies such as
hypertension, atherosclerosis, diabetes [20, 21]. ROS-
induced endothelial dysfunction is a well established
pathomechanism but currently this phenomenon was
attributed to the increased formation of the superoxide anion
- responsible for scavenging NO with the generation of
peroxynitrite and subsequent eNOS uncoupling [22], and
not to the generation of hydrogen peroxide. However, since
hydrogen peroxide is freely diffusible through cell
membranes, it can further activate inflammation, induce
apoptosis and promote endothelial dysfunction [24]. We
hereby demonstrated that H2O2 contributes to acute
experimental endothelial dysfunction dogs as it did in rats.
The role of MAOs in terminating the action of
neurotransmitters in the central and peripheral nervous
system and in the oxidation of dietary amines in
extraneuronal tissues have been extensively studied [7].
Thus, it has been shown that in vitro or in vivo application of
L-deprenyl, an irreversible MAO-B inhibitor, produced
vasodilatation via an increase in the amount of NO in brain
tissue and cerebral blood vessels [24]. NO inhibits
mitochondrial monoamine oxidase activity and decreases
outer mitochondria membrane fluidity, yet, the mechanism
by which NO inhibits MAO remains unknown at present
[25, 26].
MAO inhibitors are currently used in psychiatry and
neurology for the treatment of anxiety and depressive
disorders, Parkinson’s and Alzheimer ’s diseases,
respectively [7]. Therefore, they can be easily tested in the
settings of cardiovascular diseases, especially since there
is a growing consensus that they are increasingly
associated with depression. MAO inhibition was already
used with good results in the late 60s – early 70s in the
treatment of angina pectoris [27, 28]. Therefore, further
studies addressing the potential role of MAO inhibitors in
reversing an impaired vascular dysfunction are clearly
warranted.
Conclusions
We have here demonstrated that monoamine oxidase
A is a relevant source of ROS production, activated in
response to Ang II and that MAO-derived H2O2 impairs
endothelial function most probably via an NO mediated
mechanism. Treatment with a MAO-A reversible inhibitor
which is in current use for other pathologies partially
reversed this negative effect.
Further studies are clearly required to elucidate the
pathogenesis of the MAO-mediated endothelial dysfunction
for the proper use of available therapeutic resources.
Fig. 3. Effect of eNOS inhibition on Moclobemide (MAO-A inhibitor)
effect in Ang II-stimulated dog carotid arteries. Carotid segments
from dogs were treated in vitro 24 h with Ang II (organ culture, 100
nM) in the presence vs. absence of Moclobemide (reversible MAO-
A inhibitor) +/- eNOS inhibitor (L-NAME, 10 μM). Acetylcholine-
induced endothelium-dependent relaxation, n=6.
Fig. 2. Role of MAO-derived H2O2 in Ang II-induced endothelial
dysfunction and the effect of MAO-A inhibition. A) Acetylcholine-
induced endothelium-dependent relaxation. n=6, *p<0.05 with and
without Ang II treatment, #p<0.05 with and without moclobemide
(10 μM). B) H2O2 formation by FOX assay in the presence of
absence of the moclobemide (10 μM), n=6, *p<0.05 with and
without Ang II treatment, #p<0.05 with and without moclobemide
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